Sustained release ophthalmic, otic and nasal suspension

Details Sustained release ophthalmic, otic and nasal suspension Sustained release ophthalmic, otic and nasal suspension

2006-02-21

2006-02-21

Azpuru, Carlos A. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Matrices

C424S486000

Reexamination Certificate

active

07001615

ABSTRACT:
Sustained release suspension formulations for ophthalmic, otic and nasal administration are disclosed. The formulations comprise a basic active, a cation exchange resin, and a combination of a polymeric suspending agents to provide superior resuspendability.

REFERENCES:
patent: 2774789 (1956-12-01), Tullar
patent: 3202660 (1965-08-01), Zeile et al.
patent: 3309406 (1967-03-01), Kunz et al.
patent: 3619370 (1971-11-01), Weinstock
patent: 3655663 (1972-04-01), Wasson
patent: 3657237 (1972-04-01), Weinstock
patent: 3663607 (1972-05-01), Barrett
patent: 3836671 (1974-09-01), Barrett et al.
patent: 3857952 (1974-12-01), Wooldridge et al.
patent: 3867519 (1975-02-01), Michaels
patent: 3962414 (1976-06-01), Michaels
patent: 3987163 (1976-10-01), Rankin
patent: 4012444 (1977-03-01), Lunts et al.
patent: 4127674 (1978-11-01), Leopold
patent: 4207890 (1980-06-01), Mamajek et al.
patent: 4252984 (1981-02-01), Manoury et al.
patent: 4271143 (1981-06-01), Schoenwald et al.
patent: 4407792 (1983-10-01), Schoenwald et al.
patent: 4462982 (1984-07-01), Samejima et al.
patent: 4521414 (1985-06-01), Chiou et al.
patent: 4694022 (1987-09-01), Gerson et al.
patent: 4859462 (1989-08-01), Chow et al.
patent: 4911920 (1990-03-01), Jani et al.
patent: 4983392 (1991-01-01), Robinson
patent: 5188826 (1993-02-01), Chandrasekaran et al.
patent: 5192535 (1993-03-01), Davis et al.
patent: 5212162 (1993-05-01), Missel et al.
patent: 5461081 (1995-10-01), Ali et al.
patent: 5540930 (1996-07-01), Guy et al.
patent: 5635172 (1997-06-01), Jani et al.
patent: 5747061 (1998-05-01), Amselem et al.
patent: 5958443 (1999-09-01), Viegas et al.
patent: 0 429 732 (1991-06-01), None
patent: 0 429 732 (1991-06-01), None
patent: 2 130 585 (1984-06-01), None
patent: WO 89/06964 (1989-08-01), None
patent: WO 92/11871 (1992-07-01), None
Baldwin et al., “β1-Selective Adrenoceptor Antagonists: Examples of the 2-[4-[3-(Substituted-amino)-2-hydroxypropoxy]phenyl]limidazole Class,”J. Med. Chem., vol. 26, pp. 950-957 (1983).
Erhardt et al., “Ultra-Short Acting β-Adrenergic Receptor Blocking Agents. 3. Ethylenediamine Derivatives of (Aryloxy)propanolamines Having Esters on the Aryl Function,”J. Med Chem., vol. 26, pp. 1109-1112 (1983).
Evans et al., “β-Adrenergic Receptor Blockers as Therapeutic Agents,”J. Med. Chem., vol. 14, pp. 81-90 (1979).
Gennaro, A.Remington's Pharmaceutical Science, Mack Publishing Company, Easton, PA (1985) “How to Use Ophthalmic Ointment”.
Heath et al., Adsorption of β-Adrenoceptor Antagonists to Amberlite® Resin,Br. J. Clin. Pharmac., vol. 15, pp. 490-492 (1983).
Heyd, “Polymer-Drug Interaction: Stability of Aqueous Gels Containing Neomycin Sulfate,”J. of Pharm. Sciences, vol. 60 (9), pp. 1343-1345 (1971).
Kierstead et al., “β1-Selective Adrenoceptor Antagonists. 1. Synthesis and β-Adrenergic Blocking Activity of a Series of Binary (Aryloxy)propanolamines,”J. Med. Chem., vol. 26, pp. 1561-1569 (1983).
Large et al., “β-Adrenergic Blocking Agents,”J. Med. Chem., vol. 26, pp. 352-357 (1983).
Machin et al., “β1-Selective Adrenoceptor Antagonists. 3. 4-Azolyl-Linked Phenoxypropanolamines,”J. Med. Chem., vol. 27, pp. 503-509 (1984).
McClure et al., “Antihypertensive β-Adrenergic Blocking Agents: N-Arlkyl analogues of 2-[3-(tert-Butylamino)-2-hydroxypropoxy]-3-cyanopyride1, ”J. Med. Chem., vol. 26., pp. 649-657 (1983).
Pitha et al., “β-Adrenergic Antagonists with Multiple Pharmacophores: Persistent Blockade of Receptors,”J. Med. Chem., vol. 26, pp. 7-11 (1983).
Rohm and Hass Product Brochure for Amberlite® and Duolite® (1991).
Schoenwald et al., “Influence of High-Viscosity Vehicles on Miotic Effect of Pilocarpine,”J. of Pharm. Sciences, vol. 67(9), pp. 1280-1283 (1978).
Stalker “Enhancement of Ocular Drug Bioavailability Through the Use of Micronized, Functionalized Polymers as Carriers of Therapeutic Agents,” Dissertation submitted at the University of Kentucky (1983).
Stalker et al., “Enhancement of Ocular Drug Bioavailablity Through the Use of Drug-Resin Complexes I: Tear Film Concentrations Versus Time Profiles for Pencillin-G” Abstract of Papers Presented Before the American Pharmaceutical Association Academy of Pharmaceutical Sciences 33rdNational Meeting, San Diego, CA; vol. 12 (2), p. 116, No. 57 (1982).
Stalker et al., “Enhancement of Ocular Drug Bioavailability Through the Use of Drug-Resin Complexes II: Aqueous Humor Concentrations Versus Time Profiles for Nafcillin,” Abstract of Papers Presented Before the American Pharmaceutical Association Academy of Pharmaceutical Sciences 33rdNational Meeting, San Diego, CA; vol. 12 (2), p. 116, No. 58 (1982).
Stevens et al., “Drug Release Profiles of Ophthalmic Formulations. 1. Instrumentations,”Anal. Chem., vol. 64, pp. 715-723 (1992).

Affiliated with

Also associated with

Rating

Sustained release ophthalmic, otic and nasal suspension does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sustained release ophthalmic, otic and nasal suspension, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release ophthalmic, otic and nasal suspension will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3651276